A Phase I Trial Assessing Adalimumab (Humira), a Tumor Necrosis Factor α Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers

Trial Profile

A Phase I Trial Assessing Adalimumab (Humira), a Tumor Necrosis Factor α Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 30 Jan 2016

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Thyroid cancer
  • Focus Adverse reactions
  • Acronyms TAM-RT
  • Most Recent Events

    • 25 Jan 2016 Status changed from recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
    • 11 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top